IBDEI20A ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,34034,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34034,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Prostate
 ;;^UTILITY(U,$J,358.3,34034,1,4,0)
 ;;=4^Z85.46
 ;;^UTILITY(U,$J,358.3,34034,2)
 ;;=^5063423
 ;;^UTILITY(U,$J,358.3,34035,0)
 ;;=Z85.47^^131^1681^100
 ;;^UTILITY(U,$J,358.3,34035,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34035,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Testis
 ;;^UTILITY(U,$J,358.3,34035,1,4,0)
 ;;=4^Z85.47
 ;;^UTILITY(U,$J,358.3,34035,2)
 ;;=^5063424
 ;;^UTILITY(U,$J,358.3,34036,0)
 ;;=Z85.51^^131^1681^84
 ;;^UTILITY(U,$J,358.3,34036,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34036,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Bladder
 ;;^UTILITY(U,$J,358.3,34036,1,4,0)
 ;;=4^Z85.51
 ;;^UTILITY(U,$J,358.3,34036,2)
 ;;=^5063428
 ;;^UTILITY(U,$J,358.3,34037,0)
 ;;=Z85.528^^131^1681^89
 ;;^UTILITY(U,$J,358.3,34037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34037,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Kidney
 ;;^UTILITY(U,$J,358.3,34037,1,4,0)
 ;;=4^Z85.528
 ;;^UTILITY(U,$J,358.3,34037,2)
 ;;=^5063430
 ;;^UTILITY(U,$J,358.3,34038,0)
 ;;=Z85.6^^131^1681^80
 ;;^UTILITY(U,$J,358.3,34038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34038,1,3,0)
 ;;=3^Personal Hx of Leukemia
 ;;^UTILITY(U,$J,358.3,34038,1,4,0)
 ;;=4^Z85.6
 ;;^UTILITY(U,$J,358.3,34038,2)
 ;;=^5063434
 ;;^UTILITY(U,$J,358.3,34039,0)
 ;;=Z85.72^^131^1681^104
 ;;^UTILITY(U,$J,358.3,34039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34039,1,3,0)
 ;;=3^Personal Hx of Non-Hodgkin Lymphomas
 ;;^UTILITY(U,$J,358.3,34039,1,4,0)
 ;;=4^Z85.72
 ;;^UTILITY(U,$J,358.3,34039,2)
 ;;=^5063436
 ;;^UTILITY(U,$J,358.3,34040,0)
 ;;=Z85.79^^131^1681^94
 ;;^UTILITY(U,$J,358.3,34040,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34040,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
 ;;^UTILITY(U,$J,358.3,34040,1,4,0)
 ;;=4^Z85.79
 ;;^UTILITY(U,$J,358.3,34040,2)
 ;;=^5063437
 ;;^UTILITY(U,$J,358.3,34041,0)
 ;;=Z85.820^^131^1681^83
 ;;^UTILITY(U,$J,358.3,34041,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34041,1,3,0)
 ;;=3^Personal Hx of Malig Melanoma of Skin
 ;;^UTILITY(U,$J,358.3,34041,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,34041,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,34042,0)
 ;;=Z85.828^^131^1681^98
 ;;^UTILITY(U,$J,358.3,34042,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34042,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,34042,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,34042,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,34043,0)
 ;;=Z85.71^^131^1681^78
 ;;^UTILITY(U,$J,358.3,34043,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34043,1,3,0)
 ;;=3^Personal Hx of Hodgkin Lymphoma
 ;;^UTILITY(U,$J,358.3,34043,1,4,0)
 ;;=4^Z85.71
 ;;^UTILITY(U,$J,358.3,34043,2)
 ;;=^5063435
 ;;^UTILITY(U,$J,358.3,34044,0)
 ;;=Z65.8^^131^1681^138
 ;;^UTILITY(U,$J,358.3,34044,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34044,1,3,0)
 ;;=3^Psychosocial Circumstance Related Problems
 ;;^UTILITY(U,$J,358.3,34044,1,4,0)
 ;;=4^Z65.8
 ;;^UTILITY(U,$J,358.3,34044,2)
 ;;=^5063185
 ;;^UTILITY(U,$J,358.3,34045,0)
 ;;=Z86.11^^131^1681^115
 ;;^UTILITY(U,$J,358.3,34045,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34045,1,3,0)
 ;;=3^Personal Hx of Tuberculosis
 ;;^UTILITY(U,$J,358.3,34045,1,4,0)
 ;;=4^Z86.11
 ;;^UTILITY(U,$J,358.3,34045,2)
 ;;=^5063461
 ;;^UTILITY(U,$J,358.3,34046,0)
 ;;=Z86.13^^131^1681^82
 ;;^UTILITY(U,$J,358.3,34046,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34046,1,3,0)
 ;;=3^Personal Hx of Malaria
 ;;^UTILITY(U,$J,358.3,34046,1,4,0)
 ;;=4^Z86.13
 ;;^UTILITY(U,$J,358.3,34046,2)
 ;;=^5063463
